Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

Bernard Combe (FIL200),1 Alan Kivitz,2 Yoshiya Tanaka,3, 4 Désirée van der Heijde 5, 4, J Abraham Simon,5 Herbert S B Baraf,6 Uma Kumar 5,7, Franziska Matzkies,8 Beatrix Bartok,8 Lei Ye,8 Ying Guo,8 Chantal Tasset,9 John S Sundy,8, 10 Angelika Jahreis,8 Mark C Genovese,8 Neelufar Mozaffarian,11 Robert B M Landewé 12, Sang-Cheol Bae,13 Edward C Keystone,14 Peter Nash15

ABSTRACT

Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid arthritis (RA) despite ongoing treatment with methotrexate (MTX).

Methods This 52-week, multicentre, double-blind, placebo-controlled and active-controlled phase III trial evaluated once-daily oral filgotinib in patients with RA randomised 3:3:2:3 to filgotinib 200 mg (FIL200) or filgotinib 100 mg (FIL100), subcutaneous adalimumab 40 mg biweekly, or placebo (through week 24), all with stable weekly background MTX. The primary endpoint was the proportion of patients achieving 20% improvement in American College of Rheumatology criteria (ACR20) at week 12. Additional efficacy outcomes were assessed sequentially. Safety was assessed from adverse events and laboratory abnormalities.

Results The proportion of patients (n=1755 randomised and treated) achieving ACR20 at week 12 was significantly higher for FIL200 (76.6%) and FIL100 (69.8%) versus placebo (49.9%); treatment difference (95% CI), 26.7% (20.6% to 32.8%) and 19.9% (13.6% to 26.2%), respectively; both p<0.001). Filgotinib was superior to placebo in key secondary endpoints assessing RA signs and symptoms, physical function and structural damage. FIL200 was non-inferior to adalimumab in terms of Disease Activity Score in 28 joints with C reactive protein ≤3.2 at week 12 (p<0.001); FIL100 did not achieve non-inferiority. Adverse events and laboratory abnormalities were comparable among active treatment arms.

Conclusions Filgotinib improved RA signs and symptoms, improved physical function, inhibited radiographic progression and was well tolerated in patients with RA with inadequate response to MTX. FIL200 was non-inferior to adalimumab.

Trial registration number NCT02889796.

INTRODUCTION

Scientific innovations have changed the landscape of rheumatoid arthritis (RA) treatment. The cornerstone of RA treatment remains disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs (csDMARDs), of which methotrexate (MTX) is the gold standard, and biologic DMARDs (bDMARDs) such as those targeting cytokines (eg, tumour necrosis factor α (TNFα), interleukin 6 or interleukin 1) and B or T
cells. Availability of TNFα inhibitors (TNFαi) in the late 1990s, non-TNFαi biologics in the 2000s and recently the targeted synthetic DMARDs has helped to reduce disease severity in patients with RA. Advances in RA management have further improved patient outcomes by focusing on treat-to-target strategies, pain and inflammation reduction, and administration convenience, in addition to efficacy and safety. Despite this focus, many patients do not achieve long-term responses with currently available therapies; in one study, only 10%–21% of patients initiating csDMARDs and 12%–24% initiating TNFαi therapy achieved remission within 12 months. Potential innovations that may further improve patient outcomes in RA include new oral therapies that perform as well as, or better than, existing standard of care (SOC), particularly in patients with intolerance or inadequate response to bDMARDs (bDMARD-IR).

The FINCH phase 3 programme was developed to study filgotinib, a Janus-associated kinase (JAK)-1-preferential inhibitor, for RA treatment. In FINCH 2, filgotinib significantly improved efficacy versus placebo in bDMARD-IR patients with active RA. FINCH 3 examined filgotinib use in patients with MTX-naïve RA. To address the MTX-IR population, the FINCH 1 study examined filgotinib versus placebo or adalimumab, all with background MTX, in MTX-IR patients with active RA.

**METHODS**

**Study design and conduct**

This randomised, double-blind, 52-week, placebo-controlled and active-controlled phase III trial was conducted at 303 sites in 30 countries from 30 August 2016 to 20 June 2019. The protocol and statistical analysis plan are provided in online supplemental files 1–3. All patients provided written informed consent. An independent data monitoring committee reviewed safety data periodically. An independent adjudication committee periodically reviewed all potential major cardiovascular adverse events (MACE) and thromboembolic events.

**Study participants**

Eligible patients were ≥18 years old at the time of consent and met the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism criteria for RA diagnosis. Patients had active moderate-to-severe RA, defined as ≥6 swollen joints and ≥6 tender joints (both at screening and on day 1 despite ongoing MTX treatment for ≥12 weeks and stable at 7.5–25 mg/week for ≥4 weeks). Additional inclusion criteria were seropositivity for anticyclic citrullinated peptide (anti-CCP) antibodies or rheumatoid factor (RF); ≥1 joint erosion on hand and foot radiographs, or ≥3 erosions if negative for RF and anti-CCP; or serum C reactive protein (CRP) ≥6 mg/L. Key exclusion criteria included previous use of JAK inhibitors (JAKi) or adalimumab, prior non-response or intolerance to any bDMARD, and recent use of csDMARDs other than MTX or stably dosed hydroxychloroquine or chloroquine; concomitant, stably dosed non-steroidal anti-inflammatory drugs or glucocorticoids (≤10 mg/day prednisone/equivalent) were permitted.

**Interventions**

Eligible patients were randomly assigned (3:3:2:3) to oral filgotinib 200 mg (FIL200) or filgotinib 100 mg (FIL100) once daily, subcutaneous adalimumab 40 mg every 2 weeks, or placebo, all with stable background MTX; other concomitant medications were to be kept stable as much as possible. Study participants were blinded to treatment and received placebo tablets matching FIL200 and/or FIL100; patients not assigned to active adalimumab received matching placebo injections. At week 24, placebo-treated patients were rerandomised (1:1) to FIL200 or FIL100 and continued background MTX. Per protocol, patients without adequate treatment response (<20% improvement from baseline in either swollen joint count 66 or tender joint count 68) at week 14 or two consecutive visits after week 30 discontinued study treatment but continued study visits, using investigator-specified SOC RA therapy.

**Endpoints and assessments**

The primary efficacy endpoint was ACR20 response (20% improvement in ACR criteria) at week 12. Key secondary efficacy endpoints tested hierarchically at week 12 (unless otherwise specified) were change from baseline score on the Health Assessment Questionnaire-Disability Index (HAQ-DI), proportion of patients with Disease Activity Score in 28 joints with CRP (DAS28(CRP)) <2.6, change from baseline van der Heijde modified total Sharp score (mTSS) at week 24 (radiographic assessment details in online supplemental methods), non-inferiority of filgotinib versus adalimumab for a proportion of patients with DAS28(CRP) ≤3.2, change from baseline Short Form-36 Physical Component Summary and Functional Assessment of Chronic Illness Therapy-Fatigue score, superiority of filgotinib versus adalimumab for a proportion of patients with DAS28(CRP) ≥3.2, non-inferiority of filgotinib versus adalimumab for a proportion of patients with DAS28(CRP) <2.6, and superiority of filgotinib versus adalimumab for a proportion of patients with DAS28(CRP) ≥2.6. Other secondary endpoints included ACR50/70; low disease activity defined as Clinical Disease Activity Index (CDAI) ≤10 or Simplified Disease Activity Index (SDAI) ≤11; and remission defined as CDAI ≤2.8, SDAI ≤3.3 or Boolean remission. Safety was assessed from laboratory tests and adverse events (AEs). Positively adjudicated MACE and thromboembolic events were reported.

**Statistical analysis**

A sample size of 450 patients per filgotinib and placebo group was estimated to provide >90% power at a two-sided α of 0.05 to test the superiority of FIL200 versus placebo for change from baseline mTSS at week 24, based on other RA studies with radiography. This sample size also provided >95% power to detect a 20% difference in ACR20 for filgotinib versus placebo. Assuming similar DAS28(CRP) ≤3.2 response rates for filgotinib and adalimumab, approximately 300 adalimumab-treated patients were required to ensure >90% power at a two-sided α of 0.05 to demonstrate non-inferiority of FIL200 versus adalimumab. Consistent with regulatory guidance, non-inferiority assessments were based on the method of Liu et al., which does not require a prespecified fixed non-inferiority margin or constancy and assay sensitivity assumptions. Non-inferiority testing assessed whether the effect of each filgotinib dose (response rate difference between filgotinib and placebo) preserves >50% of the effect of adalimumab (difference in response rate between adalimumab and placebo). The 50% non-inferiority margin of DAS28(CRP) ≤3.2 and <2.6 at weeks 12 and 24 based on FINCH 1 data are presented in online supplemental table S1.

Type I error rate was controlled by hierarchical testing of primary and key secondary endpoints at a two-sided α of 0.05 (online supplemental figure S1). The primary analysis tested the superiority of FIL200 versus placebo for ACR20 at week 12 using a logistic regression model, with treatment and stratification factors included as covariates. Hypothesis testing for
Rheumatoid arthritis

key secondary endpoints commenced only after the primary endpoint reached statistical significance and proceeded sequentially until a null hypothesis was not rejected, after which exploratory p values are reported for the remaining hypotheses.

All analyses were based on data from patients who received ≥1 dose of study drug. For binary endpoints, a logistic regression model including treatment and stratification factors (geographical region, prior exposure to bDMARDs, and RF or CCP antibody positivity at screening) was used. Treatment effect on continuous endpoint change from baseline was evaluated using a mixed-effects model for repeated measures, with treatment, visit, treatment by visit interaction, stratification factors and baseline value included as fixed effects and subject as a random effect. Patients who required rescue therapy or had missing values were defined as non-responders, and non-responder imputation (NRI) was employed for primary and key secondary binary endpoint analyses. Multiple imputation was conducted to determine the impact of NRI on the robustness of results (online supplemental methods and table S2). Safety analyses of AEs and laboratory data were summarised by treatment group using descriptive statistics.

Patient and public involvement

Patients and the public were not involved in the design, conduct, reporting or dissemination of this research.

RESULTS

Study participants

A total of 1755 patients received study treatment (enrolment by country; online supplemental figure S2), and 87.4% completed the study visits through the 24-week placebo-controlled period. The reasons for discontinuation are summarised in figure 1. At week 14, 4.8% of FIL200-treated, 6.0% of FIL100-treated, 4.0% of adalimumab-treated and 8.6% of placebo-treated patients had inadequate response to treatment and were mandated to SOC. After week 24, four patients receiving FIL200, three receiving FIL100, three receiving adalimumab and two in each placebo-to-filotinib arm discontinued study drug due to lack of efficacy. Baseline demographics, concomitant medications and disease characteristics were similar among the treatment arms (table 1).

Efficacy

ACR20 responses at week 12 were significantly greater in patients receiving filgotinib versus placebo: 76.6% for FIL200 and 69.8% for FIL100 vs 49.9% for placebo (all p<0.001) (table 2, figure 2A). Significant improvements at week 12 with filgotinib versus placebo treatment were also observed in key secondary endpoints, including HAQ-DI and DAS28(CRP) <2.6 (all p<0.001) (table 2). Radiographic progression of structural joint damage was significantly reduced in both filgotinib dose arms versus placebo at week 24 (p<0.001 for FIL200; p=0.001 for FIL100) (figure 3). FIL200 was non-inferior to adalimumab at week 12 for DAS28(CRP) ≤3.2 (p<0.001); FIL100 did not

Figure 1

Patient disposition. *23 (4.8%) patients treated with filgotinib 200 mg, 29 (6.0%) patients treated with filgotinib 100 mg, 13 (4.0%) patients treated with adalimumab, and 41 (8.6%) patients treated with placebo did not have adequate response to treatment per protocol at week 14. †3 (0.7%) patients treated with filgotinib 200 mg, 2 (0.5%) patients treated with filgotinib 100 mg, 3 (1.0%) patients treated with adalimumab, 0 patient treated with placebo and randomised to filgotinib 200 mg at week 24, and 4 (2.2%) patients treated with placebo and randomised to filgotinib 100 mg at week 24 failed to maintain response to treatment per protocol after week 30. ADA, adalimumab; FIL, filgotinib; PBO, placebo; W, week.
### Table 1  Baseline demographics and disease characteristics

|                | FIL200 (n=475) | FIL100 (n=480) | ADA (n=325) | PBO (n=475) | Total (N=1755) |
|----------------|----------------|----------------|-------------|-------------|----------------|
| **Sex at birth, n (%), female** | 379 (79.8) | 399 (83.1) | 266 (81.8) | 391 (82.3) | 1435 (81.8) |
| **Age, years** | 52±12.8 | 53±12.6 | 53±12.9 | 53±12.8 | 53±12.7 |
| **Weight, kg** | 70.6±17.5 | 69.9±16.9 | 71.5±17.4 | 70.6±16.8 | 70.6±17.1 |
| **Body mass index, kg/m²** | 26.7±5.7 | 26.4±5.8 | 26.9±6.0 | 27.0±5.9 | 26.7±5.8 |
| **Race, n (%)** |                |                |             |             |                |
| White          | 312 (65.7) | 324 (67.5) | 229 (70.5) | 319 (67.2) | 1184 (67.5) |
| Asian          | 122 (25.7) | 115 (24.0) | 70 (21.5)  | 109 (22.9) | 411 (23.4)  |
| American Indian/Alaska Native | 27 (5.7)   | 27 (5.6)   | 10 (3.1)   | 12 (2.5)   | 35 (2.0)    |
| Black/African American | 6 (1.3)    | 7 (1.5)    | 10 (3.1)   | 12 (2.5)   | 35 (2.0)    |
| Other*         | 8 (1.7)    | 6 (1.3)    | 1 (0.3)    | 5 (1.1)    | 20 (1.1)    |
| **Not permitted** | 0          | 1 (0.2)    | 0           | 1 (0.2)    | 2 (0.1)     |
| **Ethnicity, n (%)** |                |                |             |             |                |
| Not Hispanic or Latino | 404 (85.1) | 399 (83.1) | 268 (82.5) | 400 (84.2) | 1471 (83.8) |
| **Duration of RA diagnosis, years** | 7.3±7.4 | 8.5±8.2 | 8.0±7.4 | 7.3±7.2 | 7.8±7.6 |
| **hsCRP, mg/L** | 16.1±21.0 | 16.7±23.0 | 14.6±18.0 | 16.3±24.1 | 16.0±21.9 |
| **Median (Q1, Q3)** | 8.8 (3.6, 21.2) | 9.0 (3.9, 20.7) | 8.0 (3.4, 17.2) | 7.5 (3.3, 19.8) | 8.2 (3.6, 19.9) |
| **≥6 mg/L, n (%)** | 298 (62.7) | 295 (61.5) | 197 (60.6) | 274 (57.7) | 1064 (60.6) |
| **RF-positive, n (%)** | 352 (74.1) | 362 (75.4) | 241 (74.2) | 365 (76.8) | 1320 (75.2) |
| **Anti- CCP-positive, n (%)** | 380 (80.0) | 381 (79.4) | 253 (77.8) | 378 (79.6) | 1392 (79.3) |
| **mTSS units§** | 32.5±47.9 | 36.7±53.1 | 34.8±55.0 | 31.6±53.2 | 33.8±52.1 |
| **Median (Q1, Q3)** | 12.0 (2.0, 45.5) | 13.0 (2.5, 52.5) | 12.5 (2.0, 45.3) | 11.5 (2.0, 37.0) | 12.0 (2.0, 43.5) |
| **Erosion score >0, n (%)¶** | 399 (84.0) | 411 (85.6) | 277 (83.2) | 404 (84.5) | 1491 (85.0) |
| **JSN score** | 18.5±25.6 | 19.9±27.3 | 19.6±28.2 | 17.6±26.9 | 18.3±26.9 |
| **bDMARD-naive, n (%)** | 458 (96.4) | 464 (96.7) | 317 (96.6) | 400 (84.2) | 1471 (83.8) |
| **MTX dose, mg/week** | 15.3±4.9 | 15.5±4.8 | 15.4±4.8 | 14.9±4.5 | 15.3±4.8 |
| **Concurrent oral steroids, n (%)** | 229 (48.2) | 229 (47.7) | 140 (43.1) | 217 (45.7) | 815 (46.4) |
| **≤5 mg/day, n (%)††** | 152 (66.4) | 160 (69.9) | 96 (68.6) | 152 (70.0) | 560 (68.7) |
| **Steroid dose, mg/day§‡‡** | 6.2±3.4 | 6.1±2.5 | 5.9±2.2 | 5.9±2.5 | 6.0±2.8 |
| **Concurrent antimalarials, n (%)** | 64 (13.5) | 59 (12.3) | 39 (12.0) | 63 (13.3) | 225 (12.8) |
| **DAS28(CRP)** | 5.8±0.9 | 5.7±1.0 | 5.7±0.9 | 5.7±0.9 | 5.7±0.9 |
| **SDAI** | 41.2±12.3 | 40.2±12.8 | 40.6±11.9 | 41.2±12.4 | 40.8±12.4 |
| **CDAI** | 39.5±11.9 | 38.6±12.2 | 39.2±11.5 | 39.6±11.7 | 39.2±11.8 |
| **SJC66** | 15±8.5 | 15±8.5 | 16±8.4 | 16±8.5 | 16±8.5 |
| **TJC68** | 25±13.5 | 25±13.4 | 24±13.2 | 24±13.5 | 24±13.4 |
| **PGA, VAS, mm** | 66±16.0 | 65±16.5 | 67±15.5 | 66±16.2 | 66±16.1 |
| **FACIT-F¶¶** | 27.6±10.7 | 27.8±10.6 | 27.2±10.2 | 26.9±10.3 | 27.4±10.5 |

Values are mean±SD.

*Includes patients recorded as Native Hawaiian/Pacific Islander and ‘Other’. Race was not recorded for one patient receiving FIL100 and one patient receiving PBO due to local regulations.

†n=1 missing.

¶n=2 missing.

§Campaign A: FIL200, n=467; FIL100, n=471; ADA, n=319; PBO, n=466.

¶¶Campaign A: FIL200, n=8 missing; FIL100, n=9 missing; ADA, n=6 missing; PBO, n=9 missing.

**FIL100, n=479; ADA, n=324.

††Percent of patients with concurrent oral corticosteroid use on first dosing date.

¶¶FIL200, n=226; FIL100, n=471; ADA, n=140; PBO, n=217.

§§FIL200, n=473; FIL100, n=479; ADA, n=323; PBO, n=474.

AAA FIL200, n=472; FIL100, n=477; ADA, n=319; PBO, n=469.

ADA, adalimumab; anti-CCP, anticyclic citrullinated protein antibody; bDMARD, biologic disease-modifying antirheumatic drug; CD41, Clinical Disease Activity Index; DAS28(CRP), Disease Activity Score in 28 joints with C reactive protein; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; FIL100, filgotinib 100 mg; FIL200, filgotinib 200 mg; HAQ-DI, Health Assessment Questionnaire-Disability Index; hsCRP, high-sensitivity C reactive protein; JSN, joint space narrowing; MCS, Mental Component Summary; mTSS, van der Heijde modified total Sharp score; MTX, methotrexate; PBO, placebo; PCS, Physical Component Summary; PGA, Physician’s Global Assessment; Q1, first quartile; Q3, third quartile; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index; SF-36, Short Form-36; SGA, Subject’s Global Assessment; SJC66, swollen joint count of 66 joints; TJC68, tender joint count of 68 joints; VAS, visual analogue scale.

Combe B, et al. *Ann Rheum Dis* 2021; 80:848–858. doi:10.1136/annrheumdis-2020-219214
Rheumatoid arthritis

Table 2  Primary and key secondary efficacy outcomes during the placebo-controlled period*

|                      | FIL200 (n=475) | FIL100 (n=480) | ADA (n=325) | PBO (n=475) |
|----------------------|----------------|----------------|-------------|-------------|
| **Primary outcome**  |                |                |             |             |
| ACR20, week 12       | 364/475        | 335/480        | 229/325     | 237/475     |
| % (95% CI)           | 76.6 (72.7 to 80.5) | 69.8 (65.6 to 74.0) | 70.3 (65.3 to 75.6) | 49.9 (45.3 to 54.5) |
| Difference vs PBO (95% CI)† | 26.7 (20.6 to 32.8) | 19.9 (13.6 to 26.2) | 20.6 (13.6 to 27.5) |             |
| P value vs placebo   | <0.001         | <0.001         | <0.001†     |            |

**Key secondary outcomes with hierarchical testing**

HAQ-DI change from baseline to week 12

|                      |               |                |             |             |
|----------------------|---------------|----------------|-------------|-------------|
| N                    | 457           | 459            | 311         | 435         |
| Means±SD             | −0.69±0.61    | −0.56±0.56     | −0.61±0.56  | −0.42±0.54  |
| Difference vs PBO (95% CI)† | −0.29 (−0.36 to −0.22) | −0.17 (−0.24 to −0.10) | −0.20 (−0.28 to −0.13) |          |
| P value vs PBO       | <0.001        | <0.001         | <0.001†     |            |

DAS28(CRP) <2.6, week 12

|                      |               |                |             |             |
|----------------------|---------------|----------------|-------------|-------------|
| n/N                  | 162/475       | 114/480        | 77/325      | 44/475      |
| % (95% CI)           | 34.1 (29.7 to 38.5) | 23.8 (19.8 to 27.7) | 23.7 (18.9 to 28.5) | 9.3 (6.6 to 12.0) |
| Difference vs PBO (95% CI)† | 24.8 (19.6 to 30.0) | 14.5 (9.7 to 19.3) | 14.4 (8.9 to 20.0) |          |
| P value vs PBO       | <0.001        | <0.001         | <0.001†     |            |

mTSS change from baseline to week 24

|                      |               |                |             |             |
|----------------------|---------------|----------------|-------------|-------------|
| N                    | 405           | 404            | 271         | 351         |
| Means±SD             | 0.13±0.9      | 0.17±0.91      | 0.16±0.95   | 0.37±1.42   |
| Difference vs PBO (95% CI)† | −0.27 (−0.43 to −0.12) | −0.25 (−0.40 to −0.10) | −0.22 (−0.39 to −0.05) |          |
| P value vs PBO       | <0.001        | <0.001         | <0.012†     |            |

Non-inferiority DAS28(CRP) ≤3.2, week 12

|                      |               |                |             |             |
|----------------------|---------------|----------------|-------------|-------------|
| n/N                  | 236/475       | 186/480        | 141/325     | 111/475     |
| % (95% CI)           | 49.7 (45.1 to 54.3) | 38.8 (34.3 to 43.2) | 43.4 (37.8 to 48.9) | 23.4 (19.5 to 27.3) |
| Difference vs PBO (95% CI)† | 24.8 (19.6 to 30.0) | 14.5 (9.7 to 19.3) | 14.4 (8.9 to 20.0) |          |
| P value vs ADA       | <0.001        | <0.001         | <0.001      |            |

**Key secondary outcomes without multiplicity adjustment**

SF-36 PCS change from baseline to week 12

|                      |               |                |             |             |
|----------------------|---------------|----------------|-------------|-------------|
| N                    | 459           | 463            | 310         | 440         |
| Means±SD             | 9.2±8.1       | 8.5±7.7        | 8.4±7.9     | 5.8±7.1     |
| Difference vs PBO (95% CI)† | 3.7 (2.8 to 4.6) | 3.1 (2.2 to 4.0) | 2.6 (1.6 to 3.6) |          |
| P value vs PBO       | <0.001        | <0.001         | <0.001      |            |

FACIT-F change from baseline to week 12

|                      |               |                |             |             |
|----------------------|---------------|----------------|-------------|-------------|
| N                    | 452           | 455            | 304         | 432         |
| Means±SD             | 9.2±9.8       | 9.1±10.2       | 8.8±9.2     | 6.8±9.9     |
| Difference vs PBO (95% CI)† | 2.8 (1.7 to 3.9) | 2.6 (1.5 to 3.7) | 2.1 (0.9 to 3.3) |          |
| P value vs PBO       | <0.001        | <0.001         | <0.001      |            |

Superiority DAS28(CRP) ≤3.2, week 12

|                      |               |                |             |             |
|----------------------|---------------|----------------|-------------|-------------|
| Difference vs ADA (95% CI)† | 6.3 (−1.0 to 13.6) | −4.6 (−11.8 to 2.6) |          |            |
| P value vs ADA       | 0.069         | 0.18           |            |            |

Non-inferiority DAS28(CRP) ≤2.6, week 12

|                      |               |                |             |             |
|----------------------|---------------|----------------|-------------|-------------|
| Difference vs PBO (95% CI)† | 2.8 (1.7 to 3.9) | 2.6 (1.5 to 3.7) | 2.1 (0.9 to 3.3) |          |
| P value vs PBO       | <0.001        | <0.001         | <0.001      |            |

Superiority DAS28(CRP) ≤2.6, week 12

|                      |               |                |             |             |
|----------------------|---------------|----------------|-------------|-------------|
| Difference vs ADA (95% CI)† | 10.4 (3.9 to 17.0) | 0.1 (−6.2 to 6.3) |          |            |
| P value vs ADA       | 0.001         | 0.99           |            |            |

*Hierarchical testing according to prespecified, US Food and Drug Administration-reviewed, statistical analysis plan. Patients who had missing values were defined as non-responders, and NRI was employed for both primary and key secondary analyses.
†Difference in response rates vs placebo or ADA for categorical outcomes; least-squares mean difference vs placebo or ADA for continuous outcomes.
‡Exploratory p value without multiplicity adjustment.

ACR20, American College of Rheumatology criteria 20% decrease from baseline; ADA, adalimumab; DAS28(CRP), Disease Activity Score in 28 joints with C reactive protein; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; FIL100, filgotinib 100 mg; FIL200, filgotinib 200 mg; HAQ-DI, Health Assessment Questionnaire-Disability Index; mTSS, van der Heijde modified total Sharp score; NRI, non-responder imputation; PBO, placebo; SF-36 PCS, Short Form 36 Physical Component Summary.

achieve non-inferiority versus adalimumab for this measure (p=0.054) (table 2).

The remaining key secondary endpoints were not adjusted for multiplicity and are presented as exploratory analyses (table 2). ACR50/70 responses at week 12 were higher following FIL200 (47.2%/26.1%), FIL100 (36.5%/18.5%) or adalimumab (35.1%/14.2%) compared with placebo (19.8%/6.7%) (figure 2B,C). Response rates for DAS28(CRP) ≤3.2 at week 12 were higher in both filgotinib dose arms and placebo (table 2). Patients receiving filgotinib achieved higher rates of
remission and low disease activity across several composite disease measures (DAS28(CRP), CDAI, SDAI, Boolean remission) versus placebo at weeks 12 and 24 (figure 4A,B). Filgotinib efficacy was sustained through week 52 (figures 2A–C and 4A,B, online supplemental tables S3 and S4, figure S3).

Changes from baseline in ACR and DAS28(CRP) components at week 12 were generally consistent with the primary and key secondary efficacy outcomes, although the effect of FIL versus adalimumab or placebo treatment was more pronounced for high-sensitivity CRP compared with other measures (online supplemental table S5). However, in post-hoc exploratory analyses, FIL200 was non-inferior to adalimumab for CDAI low disease activity and remission at weeks 12 and 24 (online supplemental table S3). In a subanalysis of proportion of patients achieving ACR20 at week 12 across countries, the placebo response rate ranged from 36.8% to 59.2% and was highest in group B (predominantly Eastern Europe) and group C (Mexico and Argentina) (online supplemental table S6).

Figure 2 Proportions of patients achieving (A) ACR20, (B) ACR50 and (C) ACR70 through week 52. Error bars show 95% CI. Additional statistical details are available in online supplemental table S3 and all response rates in online supplemental table S7. **p<0.01, ***p<0.001 versus PBO, not adjusted for multiplicity and should be considered exploratory except for ACR20 for FIL200 and FIL100 versus PBO at week 12. *p<0.05, **p<0.01,**p<0.001 versus ADA, not adjusted for multiplicity and should be considered exploratory. ACR20/50/70, 20%/50%/70% improvement from baseline by the American College of Rheumatology core criteria; ADA, adalimumab; FIL100, filgotinib 100 mg; FIL200, filgotinib 200 mg; PBO, placebo.

Figure 3 Radiographic progression through week 24. (A) mTSS change from baseline, (B) erosion score change from baseline and (C) joint space narrowing change from baseline. Data from campaign A (week 24) are shown. Supporting data are shown in online supplemental table S4. Patient numbers at each time point in (B) and (C) are the same as for (A). Error bars represent the SE of the LS mean. *p<0.05, **p<0.01, ***p<0.001 versus PBO, not adjusted for multiplicity and should be considered exploratory except for mTSS change from baseline following FIL200 and FIL100 versus PBO at week 24. Difference for mTSS change from baseline at week 24 following treatment with FIL200 or FIL100 versus ADA was explored and was not significant for either dose. ADA, adalimumab; FIL100, filgotinib 100 mg; FIL200, filgotinib 200 mg; LS, least-squares; mTSS, van der Heijde modified total Sharp score; PBO, placebo.
Safety

Treatment-emergent AEs (TEAEs) are presented in table 3. The incidence of serious TEAEs during the active-controlled period through week 52 was similar among all original active treatment arms and in patients randomised from placebo to filgotinib. During the placebo-controlled period, malignancy (excluding non-melanoma skin cancer) was reported in five patients: one (0.2%), one (0.3%) and three (0.6%) patients receiving FIL100, adalimumab and placebo, respectively. Venous thromboembolism (VTE) was reported in three patients: one (0.2%) receiving FIL200 and two (0.4%) receiving placebo, not adjusted for multiplicity and should be considered exploratory except for FIL200 and FIL100 versus placebo for DAS28(CRP) <2.6 at week 12. Non-inferior versus adalimumab.

Figure 4 Proportions of patients achieving (A) low disease activity and (B) DAS28(CRP) <2.6 or remission at weeks 12, 24 and 52. Error bars show 95% CI. Additional statistical details are available in online supplemental table S3. *p<0.05, **p<0.01, ***p<0.001 versus placebo, not adjusted for multiplicity and should be considered exploratory. ACR20, American College of Rheumatology 20% improvement; ACR50, American College of Rheumatology 50% improvement; ACR70, American College of Rheumatology 70% improvement; ASASd, American College of Rheumatology/ASES Disease Activity Score; ASASp, American College of Rheumatology/ASES Pain Score; CDAI, Clinical Disease Activity Index; DAS28, Disease Activity Score in 28 joints; DAS44, Disease Activity Score in 44 joints; DAS54, Disease Activity Score in 54 joints; DAS28(CRP), Disease Activity Score in 28 joints with C reactive protein; DAS28(SAA), Disease Activity Score in 28 joints with serum amyloid A; DAS44(SAA), Disease Activity Score in 44 joints with serum amyloid A; DAS54(SAA), Disease Activity Score in 54 joints with serum amyloid A; EULAR, European League Against Rheumatism; FAS, full analysis set; GC, glucocorticoids; GF, glucocorticoids and/or non-steroidal anti-inflammatory drugs; GTR, global target; MRI, magnetic resonance imaging; PBO, placebo; PsA, psoriatic arthritis; Psoriatic arthritis (PsA) and primary varicella. Additional details of the DVT-associated and primary varicella-associated deaths are provided in online supplemental results.

Overall, infectious and serious infectious TEAEs occurred more frequently in patients receiving filgotinib or adalimumab versus placebo through week 24. Serious infections occurring in >2 patients were pneumonia (13 patients), cellulitis (3 patients) and bronchitis (3 patients). Through week 24, herpes zoster (excluding primary varicella) occurred in all treatment arms in 0.4% of patients receiving either filgotinib dose or placebo and in 0.6% of patients receiving adalimumab. Through week 52, serious infections occurred in 2.7%, 2.7% and 3.1% and herpes zoster occurred in 1.3%, 0.8% and 0.6% of patients receiving FIL200, FIL100 and adalimumab, respectively. In 14% of patients randomised in Asia (online supplemental figure S2), the frequency of herpes zoster was 1%, 3% and 0% for patients receiving FIL200, FIL100 and adalimumab, respectively, through week 52, and 2% in placebo-treated patients through week 24. Both reported opportunistic infections were in patients receiving adalimumab: one patient with Pneumocystis jiroveci pneumonia before week 24 and one patient with active Mycobacterium tuberculosis after week 24.

Grade 3/4 changes in laboratory values are shown in table 4. Mean haemoglobin levels were stable or increased across all treatment arms, with no imbalance in individual decreased haemoglobin events or grade 3 changes. Decreases in neutrophil and lymphocyte levels were seen in filgotinib-treated and adalimumab-treated patients. Grade ≥3 lymphopenia and neutropenia were more frequent in patients receiving filgotinib versus placebo. The majority of white cell count abnormalities were grade 1/2, not associated with infection, and resolved at follow-up testing. No grade ≥3 changes in platelet counts were observed. Higher mean creatinine levels were observed in patients receiving filgotinib versus adalimumab or placebo. Grade 3/4 serum creatinine elevations were reported in three patients: one receiving FIL100 and two receiving placebo, all before week 24. Mean creatinine kinase and low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels were increased in patients treated with filgotinib versus placebo, without meaningful change in the HDL cholesterol ratio.

DISCUSSION

The FINCH 1 study assessed filgotinib, an oral JAK1-preferential inhibitor, to address the unmet needs for RA treatment in MTX-IR patients. Two doses of filgotinib were compared with adalimumab and placebo, all with background MTX. Both filgotinib doses were superior to placebo for ACR20 response and hierarchical key secondary endpoints evaluating signs and symptoms, physical function and structural damage. Although conclusions are limited for tests without multiplicity adjustment, proportions of patients achieving various measures of low disease activity and remission were generally consistent with DAS28(CRP) <2.6 and DAS28(CRP) ≤3.2 response results.

These phase III results confirm those of two phase II studies investigating filgotinib with or without MTX versus placebo in MTX-IR patients and a phase III study (FINCH 2) in bDMARD- refractory patients, and are consistent with the
Filgotinib benefits must be considered in the context of risks. In this study, serious TEAEs and discontinuations due to TEAEs were similar among treatment arms through week 24. Safety data remained consistent over the entire 52-week study. Adjudicated MACE and VTE were observed in all treatment arms at similar rates across active treatment groups. The frequency of herpes zoster was low and similar across all groups through week 24; the number of uncomplicated cases increased slightly after week 24 in the filgotinib versus adalimumab treatment arms. The low frequency of herpes zoster does not appear attributable to geography; the proportion of FINCH 1 patients enrolled in Asian countries (14%) was comparable relative to similar JAKi studies (3%–18%).25,26,31 No cases of opportunistic infection or tuberculosis were observed in filgotinib-treated patients. Rates of AEs in filgotinib-treated patients were consistent with or below those from a recent meta-analysis on JAKi treatment in RA.25 Filgotinib was associated with decreases in neutrophil, lymphocyte and platelet counts and increases in lipid, creatine kinase and creatinine levels, as previously reported for filgotinib and other JAKis.18,23–25 There were small numerical differences in frequencies of grade 3/4 neutropenia and lymphopenia in patients treated with filgotinib versus placebo. Treatment with filgotinib was associated with small increases in fasting total, LDL and HDL cholesterol without affecting fasting LDL to HDL ratio, consistent with the hypothesis that JAKi treatment suppresses elevated cholesterol ester catabolism in patients with active RA and normalises their cholesterol levels towards the range in healthy volunteers.31

Combe B, et al. Ann Rheum Dis 2021;80:848–858. doi:10.1136/annrheumdis-2020-219214

Table 3  Treatment-emergent adverse events through week 24 and week 52

|                  | PBO-controlled period (weeks 0–24) | Weeks 0–25 | PBO |
|------------------|-----------------------------------|------------|-----|
|                  | FIL200 (n=475) | FIL100 (n=480) | ADA (n=325) | PBO (n=475) | FIL200 (n=475) | FIL100 (n=480) | ADA (n=325) | PBO (n=475) |
| TEAEs, n (%)     | 287 (60.4) | 287 (59.8) | 186 (57.2) | 252 (53.1) | 352 (74.1) | 350 (72.9) | 239 (73.5) | 92 (48.4) | 97 (50.8) | 254 (53.5) |
| Any TEAE         | 21 (4.4) | 24 (5.0) | 14 (4.3) | 20 (4.2) | 35 (7.4) | 40 (8.3) | 22 (6.8) | 7 (3.7) | 8 (4.2) | 21 (4.4) |
| TE SAE           | 15 (3.2) | 9 (1.9) | 13 (4.0) | 15 (3.2) | 26 (5.5) | 15 (3.1) | 18 (5.5) | 6 (3.2) | 2 (1.0) | 15 (3.2) |
| TEAE leading to treatment discontinuation | 2 (0.4) | 1 (0.2) | 0 | 2 (0.4) | 3 (0.6) | 1 (0.2) | 1 (0.3) | 1 (0.5) | 1 (0.5) | 2 (0.4) |
| Deaths           | 31 (6.5) | 29 (6.0) | 15 (4.6) | 25 (5.3) | 43 (9.1) | 48 (10.0) | 24 (7.4) | 7 (3.7) | 6 (3.1) | 25 (5.3) |
| Nasopharyngitis   | 25 (5.3) | 33 (6.9) | 17 (5.2) | 14 (2.9) | 41 (8.6) | 49 (10.2) | 21 (6.5) | 8 (4.2) | 6 (3.1) | 14 (2.9) |
| ALT increased     | 13 (2.7) | 15 (3.1) | 14 (4.3) | 11 (2.3) | 17 (3.6) | 25 (5.2) | 22 (6.8) | 7 (3.7) | 3 (1.6) | 11 (2.3) |
| AST increased     | 9 (1.9) | 14 (2.9) | 11 (3.4) | 9 (1.9) | 12 (2.5) | 20 (4.2) | 18 (5.5) | 8 (4.2) | 3 (1.6) | 9 (1.9) |
| Nausea           | 19 (4.0) | 10 (2.1) | 4 (1.2) | 7 (1.5) | 26 (5.5) | 16 (3.3) | 6 (1.8) | 4 (2.1) | 1 (0.5) | 7 (1.5) |
| Urinary tract infection | 11 (2.3) | 8 (1.7) | 8 (2.5) | 5 (1.1) | 19 (4.0) | 20 (4.2) | 17 (5.2) | 10 (5.3) | 8 (4.2) | 6 (1.3) |
| TEAEs of special interest |
| Infectious AEs    | 133 (28.0) | 128 (26.7) | 88 (27.1) | 105 (22.1) | 206 (43.4) | 194 (40.4) | 129 (39.7) | 45 (23.7) | 39 (20.4) | 106 (22.3) |
| Serious infectious AEs | 8 (1.7) | 8 (1.7) | 8 (2.5) | 4 (0.8) | 13 (2.7) | 13 (2.7) | 10 (3.1) | 1 (0.5) | 2 (1.0) | 4 (0.8) |
| Herpes zoster     | 2 (0.4) | 2 (0.4) | 2 (0.6) | 2 (0.4) | 6 (1.3) | 4 (0.8) | 2 (0.6) | 2 (1.1) | 1 (0.5) | 2 (0.4) |
| Hepatitis B or C | 0 | 0 | 1 (0.3) | 0 | 1 (0.2) | 1 (0.2) | 1 (0.3) | 1 (0.5) | 1 (0.5) | 0 |
| Opportunistic infections | 0 | 0 | 1 (0.3) | 0 | 0 | 0 | 2 (0.6) | 0 | 0 | 0 |
| Active tuberculosis | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | 0 | 0 | 0 |
| MACE†             | 0 | 0 | 1 (0.2) | 1 (0.3) | 2 (0.4) | 0 | 2 (0.4) | 1 (0.3) | 1 (0.5) | 1 (0.5) | 2 (0.4) |
| Malignancy         |
| Excluding NMSC    | 0 | 0 | 1 (0.2) | 1 (0.3) | 3 (0.6) | 2 (0.4) | 2 (0.4) | 2 (0.6) | 0 | 0 | 3 (0.6) |
| NMSC              | 0 | 0 | 0 | 0 | 1 (0.2) | 1 (0.2) | 0 | 0 | 0 | 0 |
| VTE†              | 1 (0.2) | 0 | 2 (0.4) | 1 (0.2) | 0 | 1 (0.3) | 1 (0.5) | 0 | 2 (0.4) |
| GI perforation    | 0 | 0 | 0 | 0 | 1 (0.2) | 0 | 0 | 0 | 0 | 0 |

*TEAEs occurring in >5% of patients in a single treatment arm during either study period.
†Positively adjudicated.

ADA, adalimumab; AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FIL100, filgotinib 100 mg; FIL200, filgotinib 200 mg; GI, gastrointestinal; MACE, major adverse cardiac event; NMSC, non-melanoma skin cancer; PBO, placebo; SAE, serious AE; TE, treatment-emergent; TEAE, treatment-emergent AE; URTI, upper respiratory tract infection; VTE, venous thromboembolism.
The study excluded patients with prior bDMARD failure, so data cannot be extrapolated to bDMARD-experienced patients; filgotinib was previously compared with placebo in this population. Generalisability to patients with less active RA is potentially limited because the study enrolled patients with moderate-to-severe disease. Placebo treatment was limited to 24 weeks due to ethical concerns. An elevated placebo response was especially high in geographical regions about safety can be reached. Additional safety data will come from the integrated safety analysis across all phase II and III filgotinib trials, long-term extension study (ClinicalTrials.gov NCT03025308) and future registries.

CONCLUSIONS

In MTX-IR patients with active RA, filgotinib plus MTX reduced RA signs and symptoms, improved physical function and inhibited progression of structural joint damage. This study demonstrated non-inferiority of FIL200 plus MTX, but not FIL100 plus MTX, to adalimumab plus MTX, based on DAS28(CRP) low disease activity. Overall, filgotinib showed a favourable benefit-risk profile and both doses were well tolerated.

Author affiliations

1Rheumatology, CHU Montpellier, Montpellier, France
2Altoona Center for Clinical Research, Duncansville, Pennsylvania, USA
3First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
4Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
5Köhler & Milstein Research, Mérida, Mexico
6Medicine, Duke University Medical Center, Durham, North Carolina, USA
7Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands
8Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
9Galapagos NV, Mechelen, Belgium
10Medicine, University of Toronto, Mount Sinai Hospital, Toronto, Ontario, Canada
11Reumatología, CHU Montpellier, Montpellier, France
12Rheumatology, CHU Montpellier, Montpellier, France
13Rheumatology, CHU Montpellier, Montpellier, France
14Ichnos Sciences, New York, New York, USA
15Griffith University, Brisbane, Queensland, Australia

Acknowledgements We thank all patients and their families and the FINCH 1 investigators/site staff. Medical writing assistance was provided by Judith M Phillips, DVM, PhD, of AlphaScientia, and Emmett Glass, PhD, MBA of Red Sky Medical, both funded by Galapagos NV.
with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (Darwin 1). *Ann Rheum Dis* 2017;76:998–1008.

25 Dougados M, van der Heijde D, Chen Y-C, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. *Ann Rheum Dis* 2017;76:88–95.

26 Fleischmann R, Pangan AL, Song I-H, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. *Arthritis Rheumatol* 2019;71:1788–800.

27 Kerschbaumer A, Sepriano A, Smolen JS, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. *Ann Rheum Dis* 2020;79:744–59.

28 Kim SC, Schneeweiss S, Liu J. Risk of venous thromboembolism in patients with rheumatoid arthritis. *Arthritis Care Res* 2013;65:1600–7.

29 Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. *Circulation* 2003;107:1303–7.

30 Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis* 2020;79:685–99.

31 Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (oral strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. *Lancet* 2017;390:457–68.

32 Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. *Gastroenterology* 2020;158:1554–73. e12.

33 Charles-Schoeman C, Fleischmann R, Davignon J, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. *Arthritis Rheumatol* 2015;67:616–25.

34 Bechman K, Yates M, Norton S, et al. Placebo response in rheumatoid arthritis clinical trials. *J Rheumatol* 2020;47:28–34.